You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

March 9, 2012

Food Registration with the Thai FDA: Overcoming Pitfalls

Bangkok Post, Corporate Counsellor Column

With its diverse range of consumers seeking both traditional wares and more modern Western-influenced products, Thailand, like Vietnam and many other Asean countries, has become a hugely attractive and a lucrative market for foreign and local food manufacturers alike.

But for foreign companies that want to import products into Thailand, their first interaction with the Thai Food and Drug Administration (FDA) too often ends with a firm rebuttal, as their products are rejected for registration or they face significant delays. This is especially true if the food and drug regulators in the countries they are used to dealing with lack a strong pre-marketing review system but instead rely only on a post-marketing process to protect consumers in the event of product liability lawsuits, such as the US.

Although these FDA obstacles can be frustrating, companies can achieve success by familiarizing themselves with Thai FDA practices and preparing for potential pitfalls.

New Food Ingredients

Prior to starting the registration process for a food product, a company must first determine whether all its ingredients have already been approved by the Thai FDA. An ingredient that is commonly registered in another country may not necessarily have been registered with the FDA.

For new ingredients, the FDA will request additional supporting documents. For example, a product used in food consumption must be able to show a history of use for more than 15 years in a foreign country and/or safety data.

Companies need to make strategic decisions about whether to retain the new food ingredient in a formula. On the one hand, the new ingredient can be helpful in differentiating the product from competitors, but on the other hand companies face an extended registration process when new ingredients are included.

Misclassification of Food

Companies often have a misconception that if their products are classified and registered in a certain category in a country such as Singapore, then they would fall into the same category in Thailand. This is not necessarily the case. Prior to FDA submission, an applicant must be fully aware of: (1) the ingredient list for its products; (2) the source of the ingredients; (3) the manufacturing process; (4) the objectives of use; and (5) the targeted consumer group. These factors will allow the company to:

  • Preliminarily classify the product; and
  • Assist in answering registration questions from the Thai FDA.

Misclassifying the product will delay the registration process, because companies are not permitted to transfer a dossier from one category to another. If a category change needs to be made, then the company must restart the application.

Requirements differ from one category to another. For example, if you misclassify a dietary supplement in the food supplement category, which does not require any analysis, when it is in fact a beverage in a sealed container, then this would mean additional documents and a detailed analysis are required. This causes further delays.

These delays can be avoided by carefully preparing and reviewing product ingredients and information before considering the classification.

Preparing Your Dossier Carefully

Asean lacks a system for harmonization of food products, and thus the product dossier requirements differ between member countries. In addition, some other countries, including the US, do not necessarily issue the same types of documents required by the Thai FDA.

The Thai FDA conducts a careful substantive examination of the documents provided, and any discrepancies will further delay the registration process. Companies should ensure that all documents, as requested by the FDA, are complete and consistent. If some documents are unavailable, then be prepared to provide a suitable response to the FDA.

Health Claims on Labels

The Thai FDA takes a stricter approach to claims on labels than in other countries, including the US. For example, the Thai FDA permits nutrition claims if appropriate analysis is conducted. However, health claims—that is, claims relating to benefits, efficacies and functions of the product—are forbidden.

Foreign companies perceive the Thai FDA interpretation as very strict, as it requires a complete amendment of their labels when they are designed abroad. In some cases, however, it is worth negotiating with the FDA, as its officials are willing to learn from industry specialists. It is important for industries to work closely with the FDA in providing assistance on how to differentiate between health claims, slogans and other advertising statements.

Regional Market

Food manufacturers and importers should no longer view Thailand as a stand-alone market when targeting it for their products, but rather part of the overall Asean Economic Community that is due to take effect in 2015. Using this approach, companies can maximize efficiency by planning to register their products across several Asean countries.

Understanding the mechanisms adopted by local Asean FDAs may appear cumbersome, but with assistance from technical experts any company can enjoy a smooth product launch and reap the considerable benefits offered by the increased integration of Asean markets.

RELATED INSIGHTS​ 

July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements